- $22.18m
- $19.64m
- 14
- 19
- 53
- 18
Annual balance sheet for NanoViricides, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 13.7 | 20.5 | 14.1 | 8.15 | 4.8 |
| Prepaid Expenses | |||||
| Total Current Assets | 14 | 20.8 | 14.4 | 8.45 | 4.97 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 9.54 | 9.08 | 8.69 | 8.11 | 7.51 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 23.9 | 30.3 | 23.5 | 16.9 | 12.8 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2.16 | 0.351 | 0.413 | 0.534 | 1.36 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 2.16 | 0.351 | 0.413 | 2.03 | 1.36 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 21.8 | 29.9 | 23.1 | 14.9 | 11.5 |
| Total Liabilities & Shareholders' Equity | 23.9 | 30.3 | 23.5 | 16.9 | 12.8 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |